Akademik Veri Yönetim Sistemi
5th Eurasia Biochemical Approaches & Technologies Congress (EBAT), Antalya, Türkiye, 2 - 05 Kasım 2023, ss.48
Phenazines are low molecular weight, heterocyclic compounds that serve as versatile and
golden molecules in several industries regarding their broad-spectrum antimicrobial, antitumor, and
antiparasitic activity as well as their biological origin, and suitability to a great deal of biotechnological
applications 1,2
. The present study aimed to evaluate enzyme inhibition properties of microbial
phenazines over enzymes associated with metabolic diseases. For this purpose, phenazine derivatives
were produced in chemically defined media by P. chlororaphis subsp. aureofaciens on batch,
submerged cultures and purified through solvent extraction followed by adsorption chromatography.
Prior to the molecular docking procedure, three different phenazine derivatives were obtained and
characterized by spectroscopic techniques including FT-IR, NMR, and UV-Vis. Then the molecular
docking procedure was applied to the identified phenazine derivatives using AutoDock Vina 1.1.2. The
best docking scores and binding interactions over acetylcholinesterase (AChE), α-glycosidase (AG),
carbonic anhydrase I (hCA I) and II (hCA II), butyrylcholinesterase (BChE), and α-amylase (AA) are
analyzed by BIOVIA Discovery Studio. As empirical studies, spectrophotometric methods investigated
the inhibitory properties of commercially purchased AChE, BChE, AG, AA, and in-house purified (affinity
chromatography) hCA I and II enzymes. The kinetic parameters of each enzyme in the presence of the
inhibitors were defined and compared with clinically available inhibitors. In conclusion, the potential
use of microbial phenazine derivatives in the treatment of Alzheimer’s disease, diabetes, and glaucoma
was evaluated. To the best of our knowledge, this is the first study conducted to investigate the
anticholinergic, antidiabetic, and antiglaucoma effects of microbial phenazines